Ocular hypertension pipeline market analysis H2 2016 scrutinized in new research

The report provides comprehensive information on the therapeutics under development for Ocular Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Ocular Hypertension - Pipeline Review, H2 2016 - Companies Involved in Therapeutics Development are -

Aerie Pharmaceuticals, Inc.,Allergan Plc ,Amakem NV ,Bausch & Lomb Incorporated,Can-Fite BioPharma Ltd. ,D. Western Therapeutics Institute, Inc.,F. Hoffmann-La Roche Ltd.,Inotek Pharmaceuticals Corporation,Ironwood Pharmaceuticals, Inc.,Kowa Company, Ltd. ,Laboratoires Thea S.A. ,Laboratorios Sophia S.A. de C.V.,Lee's Pharmaceutical Holdings Limited,Lexicon Pharmaceuticals, Inc.,NicOx S.A. ,Ocular Therapeutix, Inc. ,Otsuka Holdings Co., Ltd.,pSivida Corp. ,Sanofi ,Santen Pharmaceutical Co., Ltd.,Senju Pharmaceutical Co., Ltd.,Sylentis S.A.U. ,ViSci Ltd.

The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Access complete report of 137 pages @ www.rnrmarketresearch.com/contact…ame=701995

Scope

• The report provides a snapshot of the global therapeutic landscape of Ocular Hypertension
• The report reviews pipeline therapeutics for Ocular Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved Ocular Hypertension therapeutics and enlists all their major and minor projects
• The report assesses Ocular Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news related to pipeline therapeutics for Ocular Hypertension

Inquire more about this market research report @ www.rnrmarketresearch.com/contact…ame=701995

Reasons to access

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline